Role of intestinal glucagon-like peptide-1 in impaired counterregulatory responses to hypoglycemia  

作　　者：Manjunath Havalappa Dodamani Juniali Hatwal Akash Batta 

机构地区：[1]Department of Endocrinology,Rukmini Hormone Superspeciality Hospital,Bagalkot 587101,Karnātaka,India [2]Department of Internal Medicine,Post Graduate Institute of Medical Education&Research,Chandigarh 160012,India [3]Department of Cardiology,Dayanand Medical College and Hospital,Ludhiana 141001,Punjab,India

出　　处：《World Journal of Diabetes》2024年第12期2394-2398,共5页世界糖尿病杂志（英文）

摘　　要：Patients with type 1 diabetes mellitus(T1DM)experience multiple episodes of hypoglycemia,resulting in dysfunctional counter-regulatory responses with time.The recent experimental study by Jin et al explored the role of intestinal glucagon-like peptide-1(GLP-1)in impaired counter-regulatory responses to hypoglycemia.They identified intestinal GLP-1 along with GLP-1 receptor(GLP-1R)as the new key players linked with impaired counter-regulatory responses to hypoglycemia in type 1 diabetic mice.They also demonstrated that excessive expression of GLP-1 and GLP-1R was associated with attenuated sympathoadrenal responses and decreased glucagon secretion.The study has enormous clinical relevance as de-fective counter regulation and hypoglycemia unawareness negatively impacts the intensive glycemic management approach in this group of patients.However,the physiological processes must be validated in dedicated human studies to compre-hensively understand the pathophysiology of this complex relationship,and to clarify the true extent of impaired hypoglycemia counter regulation by intestinal GLP-1.For now,following the results of the index study and other similar studies,GLP-1 analogues usage in T1DM must be carefully monitored,as there is an inherent risk of worsening the already impaired counter-regulatory responses in these patients.Further studies in the future could identify other key players in-volved in this clinically relevant interaction.

关 键 词：Glucagon-like peptide-1 Type-1 diabetes mellitus HYPOGLYCEMIA Counter-regulatory responses CATECHOLAMINES Adrenergic response GLUCAGON 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]